Close Menu

By Ben Butkus

Gen-Probe this week reported record revenues of $158.2 million in the fourth quarter of 2011, driven primarily by sales of clinical diagnostics and blood screening products.

The positive performance was primarily fueled by domestic and international growth of its Aptima Combo 2 assay for chlamydia and gonorrhea; and by increased shipments of assays and Tigris instruments to blood-screening partner Novartis, the company said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two researchers are calling for education for scientists on defending facts.

Researchers were among those who marched in London this weekend to call for another vote on Brexit.

Duke has agreed to pay $112.5 million to settle a lawsuit regarding its handling of data falsified by biologist Erin Potts-Kant. 

In PLOS this week: genetic factors influencing inorganic arsenic metabolism and toxicity, a germline variant in the cell adhesion molecule-coding gene DSCAM, and more.

Mar
27
Sponsored by
Swift Biosciences

Sequencing workflows require library quantification and normalization to ensure data quality and reduce cost. 

May
08
Sponsored by
Sysmex Inostics

This webinar will present recent evidence that demonstrates how incorporating circulating tumor DNA (ctDNA) assessments into real-world patient management can influence patient care decisions, alter radiographic interpretations, and impact clinical outcomes.